Curis to Present at Upcoming Investor Conferences
LEXINGTON, Mass., Feb. 15, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS),
an oncology-focused company seeking to develop next generation targeted drug
candidates for cancer treatment, today announced that the Company will be
presenting at the following upcoming conferences in New York City:
oCiti 2013 Global Healthcare Conference – Monday, February 25, 2013 at 3
p.m. EST. A corresponding audio webcast of this presentation can be
accessed by visiting:
oRBC Capital Markets 2013 Healthcare Conference - Tuesday, February 26,
2013 at 2:05 p.m. A corresponding audio webcast of this presentation can
be accessed by visiting:
The presentations are scheduled to take place in a fireside chat format in
which Daniel Passeri, President and Chief Executive Officer, will provide a
brief overview of the Company's business strategy and pipeline of small
molecule targeted cancer drug candidates, after which an equity analyst will
moderate a question and answer session.
The audio webcasts will be archived shortly after the live events and
available for 30 days following the conference.
About Curis, Inc.
Curis is an oncology-focused drug development company seeking to develop and
commercialize next generation targeted small molecule drug candidates for
cancer treatment. Erivedge® is the first and only FDA-approved medicine for
the treatment of advanced basal cell carcinoma and is being commercialized and
developed by Roche and Genentech, a member of the Roche Group, under a
collaboration agreement between Curis and Genentech. Curis is also leveraging
its experience in targeting signaling pathways to develop proprietary targeted
cancer programs, including CUDC-427, a small molecule antagonist of IAP
proteins, and CUDC-907, a dual PI3K and HDAC inhibitor. For more information,
visit Curis' website at www.curis.com.
The Curis, Inc. logo is available at
CONTACT: For More Information:
Michael P. Gray
Chief Financial Officer
Curis, Inc. Logo
Press spacebar to pause and continue. Press esc to stop.